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Abstract
Background: Cerebral amyloid angiopathy (CAA) is typified by the cerebrovascular deposition of amyloid. The
mechanisms underlying the contribution of CAA to neurodegeneration are not currently understood. Although
CAA is highly associated with the accumulation of amyloid beta (Aβ), other amyloids are known to associate with
the vasculature. Alzheimer’s disease (AD) is characterized by parenchymal Aβ deposition, intracellular accumulation
of tau, and significant neuroinflammation. CAA increases with age and is present in 85–95% of individuals with AD.
A substantial amount of research has focused on understanding the connection between parenchymal amyloid
and glial activation and neuroinflammation, while associations between vascular amyloid pathology and glial
reactivity remain understudied.
Methods: Here, we dissect the glial and immune responses associated with early-stage CAA with histological, biochemical,
and gene expression analyses in a mouse model of familial Danish dementia (FDD), a neurodegenerative disease
characterized by the vascular accumulation of Danish amyloid (ADan). Findings observed in this CAA mouse model were
complemented with primary culture assays.
Results:We demonstrate that early-stage CAA is associated with dysregulation in immune response networks and lipid
processing, severe astrogliosis with an A1 astrocytic phenotype, and decreased levels of TREM2 with no reactive microgliosis.
Our results also indicate how cholesterol accumulation and ApoE are associated with vascular amyloid deposits at the early
stages of pathology. We also demonstrate A1 astrocytic mediation of TREM2 and microglia homeostasis.
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Conclusion: The initial glial response associated with early-stage CAA is characterized by the upregulation of
A1 astrocytes without significant microglial reactivity. Gene expression analysis revealed that several AD risk
factors involved in immune response and lipid processing may also play a preponderant role in CAA. This
study contributes to the increasing evidence that brain cholesterol metabolism, ApoE, and TREM2 signaling
are major players in the pathogenesis of AD-related dementias, including CAA. Understanding the basis for
possible differential effects of glial response, ApoE, and TREM2 signaling on parenchymal plaques versus
vascular amyloid deposits provides important insight for developing future therapeutic interventions.
Keywords: Cerebral amyloid angiopathy (CAA), Astrogliosis, Alzheimer’s disease (AD), Neuroinflammation,
Triggering receptor expressed on myeloid cells 2 (TREM2), Vascular amyloid
Introduction
Alzheimer’s disease (AD) is the most common form of de-
mentia and is characterized by the extracellular deposition
of parenchymal ß-amyloid (Aß), intracellular accumula-
tion of tau as neurofibrillary tangles (NFTs), synaptic loss,
and significant inflammation [1, 2]. Cerebral amyloid
angiopathy (CAA) is typified by the cerebrovascular de-
position of amyloid and has a close molecular relationship
with AD while remaining clinically distinct. Vascular
amyloid accumulation is present in approximately 85–
95% of individuals with AD [3, 4], positioning CAA as one
of the strongest vascular contributors to age-related cogni-
tive decline [5, 6]. The mechanisms responsible for CAA
pathogenesis and its downstream effects on the brain are
complex and incompletely understood. Despite the strong
association of CAA with Aß accumulation [4], other amy-
loids also associate with the vasculature, suggesting that
CAA is a group of biochemically and genetically diverse
disorders unified by amyloid deposit accumulation in ar-
terial blood vessel walls, and, in some cases, capillaries of
the CNS parenchyma and leptomeninges [7–9].
Increasing evidence suggests a link between neuroin-
flammation and neuronal dysfunction in AD, orchestrated
by the progressive activation of microglia and astrocytes,
leading to the overproduction of pro-inflammatory mole-
cules [10]. Microglial activation occurs early in AD path-
ology [11–13] with known roles in phagocytic activity;
however, in the vicinity of amyloid plaques, these glial
cells become pro-inflammatory, contributing to neurotox-
icity in the late stages of disease [14, 15]. Astrocytes are
also suggested to play a key role in AD progression and
can be activated by amyloid plaques, resulting in the over-
expression of cytokines and excessive oxidative stress [16].
The dysfunction between astrocytes and the neighboring
neurons disrupts synaptic connections and initiates a cas-
cade of neuronal injury [17, 18]. It has recently been
shown that activation of microglia and astrocytes might
not be independent events [19], and that activated micro-
glia can directly polarize a subset of astrocytes (designated
A1 astrocytes) toward a neurotoxic phenotype [19]. This
astrocytic subtype is characterized by an increased
expression of complement 3 (C3) [19]. A1 astrocytes have
been identified in human cases and mouse models for AD,
Huntington’s disease (HD), ALS, multiple sclerosis (MS),
Parkinson’s disease (PD), prion disease, and frontotem-
poral dementia (FTD) [19–22]; however, the presence of
A1 astrocytes has yet to be reported in the context of
CAA.
Over 40% of genes identified as late-onset AD (LOAD)
risk factors are immune-related genes predominantly
expressed in microglia and astrocytes [23–25], enhancing
the connection of the immune system to AD pathogen-
esis. Over the past decades, the molecular and cellular
connections between parenchymal amyloid and glial acti-
vation and neuroinflammation have been widely studied
[13, 26], while the relationship between vascular amyloid
pathology and glial reactivity has mainly been reported
based on neuropathological observations [27–29]. For in-
stance, TREM2, one of the most studied AD-immune risk
factors, has always been analyzed in the context of paren-
chymal amyloid [30–34], but no study has described its re-
lationship with vascular amyloid pathology.
Therefore, we decided to dissect the glial responses as-
sociated with early-stage CAA in a mouse model of fa-
milial Danish dementia (FDD). FDD is characterized by
the presence of CAA, consisting of the ~ 4-kDa ADan
amyloid, in leptomeninges and vessels of the gray and
white matter. Genetic analysis in patients with FDD re-
vealed the presence of a 10-nucleotide duplication inser-
tion in the 3′-end of the coding region of the BRI2 gene.
This frameshift mutation generates an ADan precursor
protein of 277 amino acids, of which the ~ 4-kDa ADan
amyloid subunit comprises the last 34 amino acids [35].
Cotton wool-like plaques in the vicinity of blood vessels
with amyloid and tau NFTs are also observed in FDD
patients [36]. The mouse model for FDD (Tg-FDD) used
in this study consistently exhibits CAA, primarily in
leptomeningeal cerebellar vessels [37] and in the large
and medium-sized parenchymal and penetrating vessels
of the brain. At a late stage of CAA pathology, perivas-
cular tau immunoreactive deposits and qualitative glial
activation have also been observed in this model [38].
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These observations make the Tg-FDD mice an ideal
model for the study of glial reactivity and neuroimmune
responses in early-stage CAA pathology.
In the present study, we show that early-stage vascular
amyloid pathology in the Tg-FDD model is associated
with severe astrogliosis with an A1 astrocytic phenotype
without significant reactive microgliosis. We also ob-
served that a genetic network of immune and lipid pro-
cessing genes is highly dysregulated, directly impairing
cholesterol, ApoE, and TREM2. Our results suggest that
the lipid-ApoE-TREM2 pathway could play a preponder-
ant role in CAA, as previously described in AD, and that
in the context of vascular amyloid, astrogliosis is an early




Tg-FDD and wild-type C57/BL6J (WT) (JAX stock
#000664) male and female mice were used for our ex-
periments, including cellular, biochemical, and immuno-
histochemistry (IHC) analyses. The Tg-FDD mouse
model expresses an FDD-associated human mutant BRI2
transgene that leads to the vascular accumulation of
ADan amyloid [37]. Mice were housed at the Indiana
University School of Medicine (IUSM) animal care facil-
ity and were maintained according to USDA standards
(12-hr light/dark cycle, food and water ad libitum), per
the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health, Bethesda, MD). Animals
were anesthetized and euthanized according to the
IUSM Institutional Animal Care and Use Committee-
approved procedures. Mice were deeply anesthetized
prior to decapitation. After sacrifice, brains were re-
moved and stored at − 80 °C or formalin-fixed as previ-
ously described [37]. For all described experiments, 3- or
9-month-old animals were utilized.
Mouse brain samples preparation and immunoblot
analysis
WT and Tg-FDD brains were homogenized at a 1:10 (w/
vol) ratio of brain and T-PER tissue protein extraction
reagent with complete protease inhibitor cocktail
(Roche), then sonicated for 30 s. Samples were then cen-
trifuged at 13,200 rpm for 15 min at 4 °C. Next, samples
were run on a NuPAGE 4–12% Bis-Tris protein gel
(Invitrogen) and transferred to a nitrocellulose mem-
brane. Primary antibodies used were anti-ApoE (1:1000,
AB1907, Abcam), anti-TREM2 (1:10000, AF1729, R&D),
and anti-Vinculin (1:10000, V9131, Sigma). The second-
ary antibodies used were goat anti-mouse HRP IgG (1:
1500, A16066, Invitrogen) and goat anti-rabbit HRP IgG
(1:1500, PI31460, Invitrogen). Western blot (WB) quan-
tification results are expressed as the ratio of ApoE or
TREM2 normalized by the loading control Vinculin. In
all cases, we considered the control group to be 100%.
Brain sections immunofluorescence
Paraffin sections were deparaffinized in xylene and rehy-
drated in ethanol (EtOH) and washed with deionized
water. Then, the sections were heated with a microwave
oven in low pH antigen retrieval solution (eBioscience)
twice for 4 min each. After washing in PBS twice for 5
min each, the sections were blocked with PBS 5% goat
serum, 5% horse serum, 2% fish gel, and 0.01% Triton
X-100 for 1 h at room temperature (RT). Sections were
then incubated overnight at 4 °C with the following anti-
bodies: anti-GFAP (G3893, Sigma-Aldrich), anti-IBA1
(MABN92, Millipore), anti-CD11B (1:100, AB8878,
Abcam), anti-C3 (PA5-21349, ThermoFisher), anti-
ADan 1699 (gift from Dr. Ruben Vidal), anti-Desmin
(smooth muscle actin) (PA5-21349, Millipore), anti-
ApoE (AB1907, Abcam), and anti-TREM2 (AF1729,
R&D) diluted 1:100 in blocking solution. The next day,
sections were quickly washed 3 times in PBS and incu-
bated with 1:500 biotinylated horse anti-mouse antibody
(BA-200, Vector) and/or biotinylated goat anti-rabbit
antibody (BA-1000, Vector) for 1 hr at RT. Thirty mi-
nutes in advance, the Vectastain Elite ABC peroxidase
kit (PK-6100, Vector) was prepared according to the
manufacturer’s instructions. After the secondary anti-
body incubation, sections were incubated with the A + B
solution for 30 min at RT. After 3 quick washes with
PBS, tyramide dyes were prepared 1:500 in PBS, and
slides were incubated with them for 10 min at RT. Slides
were incubated with 3% H2O2 for 10 min at RT to stop
peroxidase activity. Vascular amyloid was stained with
1% Thioflavin-S for 8 min at RT, followed by two washes
in EtOH 50% and 30% for 3 min each, and a final wash
in deionized water for 5 min. For cholesterol detection,
sections were stained with filipin at a concentration of
250 μg/mL and incubated overnight at 4 °C, then rinsed
in PBS 3 × 5 min in the dark to prevent fading. Finally,
sections were washed in PBS and mounted with Vecta-
shield mounting medium with or without DAPI (Vector
Laboratories).
Astrocytes and microglia primary cell culture
Primary glial cell cultures were prepared from newborn
(postnatal day 0–3) brain cortex of C57/BL6J mice.
Briefly, animals were euthanized, and their brains ex-
tracted. Brains were cut into small pieces, collected in
HBSS (H9269, Sigma), and treated with 2.5% trypsin
(15090-046, Gibco) and 1% DNase (EN0521, Thermo) at
37 °C for 15 min. Then, the tissue was disaggregated by
pipetting, passed through a 70-μm pore cell strainer
(352350, Corning), and collected in FBS. Cells were cen-
trifuged for 5 min at 1000×g, and the obtained pellet was
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resuspended in 10mL glial medium (Advanced DMEM/
F12, 10% FBS, 100 g/mL streptomycin, 100 UI/mL peni-
cillin, 200 μg/mL glutamine). Cells were then counted
using a Luna Dual Fluorescence Cell Counter (Logos
Biosystem). Cells were plated into 75-cm2 cell culture
flask at a density of 1 × 106 and incubated until 90%
confluent, changing the media every 2 days. For primary
microglia cell culture, confluent flasks were shaken for 1
hr at 200 rpm at 37 °C to detach microglial cells. Then,
the supernatants containing microglia were collected
and centrifuged for 5 min at 300×g. The cells were resus-
pended into 1mL of glial media and counted using an
automatic cell counter (Logos Biosystem) and seeded in
6-well culture plates for further experiments. The flask
was treated with 0.5% trypsin (15400054, Gibco) for 10
min at 37 °C to detach the astrocytes. Then, the super-
natant was collected, centrifuged at 300×g for 5 min, and
the pellet was resuspended in glial medium. Astrocytes
were quantified using an automated cell counter (Logos
Biosystem) and seeded into 12-well (2 × 105 cells) plates
for further experiments. Primary astrocytes were treated
with A1 inducing cocktail IL-1α (3 ng), TNFα (30 ng),
and C1q (400 ng) for 24 h to promote A1 induction. The
next day, media was replaced with fresh serum-free
media and was allowed to condition for another 24 h,
which we define as astrocytic conditioned media (ACM).
Control-ACM or A1-ACM was then collected and
lyophilized with a Speed Vac Plus SC110A and resus-
pended in 500 μL of PBS. The total protein concentra-
tion was determined using the Pierce BCA protein assay
kit (23246, Thermo Scientific), and 50 μg of total protein
was added to mouse primary microglia.
Cell culture immunofluorescence
Astrocytes or microglia were seeded at 2 × 105 cells/well
in 18 mm diameter coverslips. Once the culture reached
90% confluence, the cells were fixed in PBS containing
4% paraformaldehyde (PFA) for 15 min. Cells were
permeabilized for 5 min at RT in 0.25% Triton X-100 in
PBS, washed twice with PBS, and incubated for 1 h at
37 °C in PBS containing 5% goat, 5% horse serum, and
2% fish gel (blocking solution). Cells were then incu-
bated overnight at 4 °C in primary antibody diluted 1:
100 in blocking solution with anti-IBA1 (MABN92,
Millipore) and anti-TREM2 (AF1729, R&D). After incu-
bation, cells were washed with PBS, then incubated with
Alexa 488-conjugated goat anti-mouse antibody (1:100,
Invitrogen) and Alexa 568-conjugated goat anti-rabbit
antibody (1:100, Invitrogen) for 1 h at RT, then washed
with PBS and mounted with Vectashield mounting
medium with DAPI (Vector Laboratories). Samples were
examined using a Nikon A1-R laser scanning confocal
microscope coupled with Nikon AR software for orthog-
onal images of reconstructed three-dimensional views.
At least 5–10 cells were analyzed from each image. Eight
to ten images were used for each experiment, and three
independent culture experiments were performed.
Microscopy and image analysis
We used the ImageJ software (NIH) to create one index
that represented changes in both astrocyte and micro-
glia. The number of C3 (+), GFAP (+), or IBA1 (+)
pixels was divided by the total number of pixels in the
image and expressed as a GFAP (+) or IBA1 (+) area %
[39] or C3 (+) GFAP (+) cells % [19]. For colocalization
analysis, the ImageJ Coloc2 plugin was used for quantifi-
cation and expressed as a percentage (% Colocalization
Area). Microglia or astrocyte cell morphology was ana-
lyzed using IBA1 or GFAP and nuclear staining for Dapi.
Cells were analyzed for the number of glial branches and
junction using cross-sectional measurements of 10–30
randomly selected cells from 5 different micrographs per
animal obtained from 20 μm image z-stacks as described
[40]. The z-stack images for IBA1 or GFAP were ob-
tained with a × 63 objective with a × 0.7 zoom and a
0.2-μm z-step. To fully analyze the cellular processes,
only IBA1 (+) or GFAP (+) labeled cells in which the cell
body was located toward the middle portion of the z-
plane were selected for imaging. For every single stain-
ing, as a negative control, primary antibodies were omit-
ted to determine background and autofluorescence (not
shown). WT and Tg-FDD (3–4 animals per genotype)
cerebral cortex and cerebellum were examined using a
Leica DMi 8 epifluorescence microscope coupled with
the LAS X program (Leica) or Nikon A1-R laser scan-
ning confocal microscope coupled with Nikon AR soft-
ware (Nikon).
qPCR
Total RNA was isolated from mouse brains with the
RNeasy Plus Universal Mini Kit (Qiagen). cDNA was
prepared from 1 μg total RNA with High-Capacity
cDNA reverse transcription kit (Life Technologies). All
qPCRs were performed on QuantStudio 6 Flex Real-
Time PCR system (Life Technologies). The mouse
TREM2 relative gene expression was evaluated with the
delta Ct method using Taqman probe sets (TREM2:
Mm00451744_m1, GAPDH 4351309, Life Technologies)
and TaqMan Universal PCR Master Mix.
RNA sequencing
Library preparation and sequencing
Three mice per group were used for RNA sequencing
experiments. The cerebellum was homogenized in Tri-
zol, and total RNA was isolated by chloroform extraction
as previously described [41]. The concentration and
quality of total RNA samples were first assessed using an
Agilent 2100 Bioanalyzer. An RNA Integrity Number
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(RIN) of five or higher was required to pass the quality
control. Then, 500 ng of RNA per sample was used to pre-
pare a dual-indexed strand-specific cDNA library using
TruSeq Stranded mRNA Library Prep Kit (Illumina). The
resulting libraries were assessed for quantity and size dis-
tribution using a Qubit and an Agilent 2100 Bioanalyzer,
respectively. Two hundred picomolar pooled libraries
were utilized per flowcell for clustering amplification on
cBot using HiSeq 3000/4000 PE Cluster Kit and
sequenced with 2 × 75 bp paired-end configuration on
HiSeq4000 (Illumina) using HiSeq 3000/4000 PE SBS Kit.
A Phred quality score (Q score) was used to measure the
quality of sequencing. More than 97% of the sequencing
reads reached Q30 (99.9% base call accuracy).
Sequence alignment and gene counts
The sequencing data were first assessed using FastQC
(Babraham Bioinformatics, Cambridge, UK) for quality
control. Then, all sequenced libraries were mapped to
the mm10 mouse genome using STAR RNA-Seq aligner
[42] with the following parameter: “--outSAMmapqUni-
que 60.” The reads distribution across the genome was
assessed using bamutils (from ngsutils) [43]. Uniquely,
mapped sequencing reads were assigned to mm10 refSeq
genes using featureCounts (from subread) [44] with the
following parameters: “-s 2 -p –Q 10.” Quality control of
sequencing and mapping results was summarized using
MultiQC [45]. Genes with read count per million (CPM)
> 0.5 in more than 3 of the samples were kept. The data
were normalized using TMM (trimmed mean of M
values) method. Differential expression analysis was per-
formed using edgeR [46, 47]. False discovery rate (FDR)
was computed from p values using the Benjamini-
Hochberg procedure.
Genomic pathway analysis
Ingenuity Pathway Analysis (IPA) core analysis was used
to identify the perturbed gene networks in 9-month-old
Tg-FDD mice compared to WT mice. The differential
expression (DE) cutoff we used in the analysis is fold
change greater than 1.2 and adjusted p value lower than
0.05. In the network figure generated by IPA, the genes
marked by red color are upregulated while the genes
marked by green are downregulated, and the main bio-
logical function of the network was provided. Then, for
a specific perturbed gene network of interest, a heatmap
showing differential expression of genes was generated
to visualize the expression perturbation of genes con-
tained in the network. Genes of interest were cross-
referenced with the Agora open access portal. Agora
hosts evidence for whether or not genes are associated
with Alzheimer’s disease (AD). Agora also contains a list
of over 500 nascent drug targets for AD that were nomi-
nated by AD researchers. The list of nominated targets
was contributed by researchers from the National Insti-
tute on Aging’s Accelerating Medicines Partnership in
Alzheimer’s Disease (AMP-AD) consortium as well as
other research teams. Other evidence presented in Agora
was either generated by AMP-AD research teams or is
aggregated from publicly available data sources [48, 49].
Statistical analyses
Experimental analysis and data collection were per-
formed blind unless otherwise stated. P values were de-
termined using the appropriate statistical method via
GraphPad Prism as described. Statistical comparisons
were made using a two-tailed unpaired Student’s t test.
Data are presented as mean ± SEM unless otherwise
stated. *, **, ***, and **** denote p < 0.05, p < 0.01, p <
0.001, and p < 0.0001, respectively.
Data availability
The accession number for the RNA-Seq data reported in
this paper is Gene Expression Omnibus (GEO):
GSE150394.
Results
Reactive astrogliosis in early-stage vascular amyloid
pathology in Tg-FDD mice
Reactive gliosis is a hallmark of many human neurode-
generative diseases, including AD [50]; however, investi-
gations into glial activation driving neuroinflammation
and neurodegeneration have predominantly focused on
parenchymal amyloid accumulation, with the contribu-
tion of vascular amyloid accumulation remaining under-
studied. To dissect glial responses associated with early-
stage CAA in detail, we performed histological analyses
of 9-month-old Tg-FDD mice as this age represents
early-stage vascular amyloid accumulation [37]. Thio-S
staining of brain sections from Tg-FDD mice revealed
the presence of vascular amyloid deposits in the cortex,
hippocampus, and cerebellum (Sup. Fig. 1) as previously
reported [37]. Since changes in area coverage by astro-
cytes or microglia is a highly reliable measure of glial re-
activity [51, 52], we stained brain sections for GFAP
(astrocytes) and IBA1 (microglia) markers and quantified
area coverage of each in the cortex, hippocampus, and
cerebellum of WT and Tg-FDD mice. We observed se-
vere astrogliosis with robust GFAP staining in all three
brain regions in Tg-FDD mice in comparison with WT
mice. Surprisingly, no significant change in microglial
immunoreactivity was observed (Fig. 1a, b) The absence
of microglial reactivity was confirmed with CD11B stain-
ing (Sup. Fig. 2). Triple staining for Thio-S, GFAP, and
α-SMA (smooth muscle actin), a vascular cell marker
[53], revealed that astrogliosis is accentuated in perivas-
cular regions in 9-month-old Tg-FDD mice in compari-
son with WT mice (Sup. Fig. 3). Immunofluorescence
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for glial markers in brains from 3-month-old Tg-FDD
mice, an age when no vascular amyloid is observed [37],
revealed no astrogliosis (Sup. Fig. 4). This suggests that
astrocytic reactivity is a response to CAA pathology, spe-
cifically, in this mouse model.
As glial morphology, function, and reactivity are
closely related [54], we performed morphometric ana-
lyses to assess changes in individual astrocytes or micro-
glia. In Tg-FDD mice, there is a significant increase in
the number of astrocytic branches and junctions in com-
parison with WT (Fig. 2a, b); however, no significant
changes were observed in microglia morphology (Fig. 2c,
d). Overall, these results indicate that reactive astroglio-
sis is an early event that occurs without significant
microgliosis in the pathogenesis of CAA in the Tg-FDD
model.
A1 astrocytes are highly abundant in Tg-FDD mice
A1 Astrocytes are a newly identified astrocyte subclass
triggered in response to injury, disease, and inflammatory
factors. These astrocytes contribute to neuronal death in
AD, Huntington’s disease (HD), ALS, multiple sclerosis
(MS), Parkinson’s disease (PD), prion disease, and fronto-
temporal dementia (FTD) [19–22]. To determine if A1
astrocytes are present in the context of CAA, we immuno-
stained brain sections with C3, a characteristic and signifi-
cantly upregulated gene used as a specific marker of A1
astrocytes [19]. C3+ astrocytes were present in both WT
and Tg-FDD mice; however, there was an increase of C3+
astrocytes in Tg-FDD mice in both the hippocampus and
cerebellum (Fig. 3). Interestingly, when the intensity plot
profiles of C3 and GFAP were analyzed, there was a larger
overlap of both markers in Tg-FDD mice in both of these
brain regions, indicating a major presence of C3+ astro-
cytes in these animals (Fig. 3a, d). Additionally, we ana-
lyzed the percentage of individual GFAP+ cells that were
also C3+ in both hippocampus and cerebellum. We found
that in the hippocampus, 65% of GFAP+ cells were also
C3+ in Tg-FDD mice, compared with 39% in WT mice
(Fig. 3b). In the cerebellum, 70% of GFAP+ cells were C3+
in Tg-FDD mice compared with 39% in WT mice (Fig. 3e).
When analyzing the percent colocalization area of C3+
GFAP+ cells, 85% corresponded to C3+GFAP+ cell area in
Tg-FDD mice compared with 22% in WT in the hippo-
campus (Fig. 3c), and 92% in Tg-FDD mice versus 20% in
WT from the cerebellum (Fig. 3f). Overall, these observa-
tions indicate a strong presence of A1 astrocytes during
the early stages of CAA pathology in Tg-FDD mice.
Fig. 1 Glial immunoreactive changes in Tg-FDD mice. a Double-stained immunofluorescent images of amyloid (Thio-S, green) and astrocytes (GFAP,
red). Quantification of GFAP+ area (%) of WT or Tg-FDD mice. b Double-stained immunofluorescent images of amyloid (Thio-S, green) and microglia
(IBA1, red). Quantification of IBA1+ area (%) of WT or Tg-FDD mice. All are representative images of 9-month-old mice. Results are shown as the mean
± SEM of n = 3–4, where *p < 0.05 and **p < 0.01 as determined by unpaired Student’s t test. Scale bar 100 μm
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Dysregulation of immune response and lipid processing
networks associated with CAA
To analyze global transcriptional changes in response to
CAA, we performed RNA-Seq analysis on 9-month-old
WT and Tg-FDD mice. We used IPA core analysis to
identify perturbed gene networks in Tg-FDD mice com-
pared with WT. Remarkably, one of the top gene net-
works identified in the Tg-FDD model was associated
with immune response and lipid processing genes
(Fig. 4). Noteworthy, genetic analysis has previously im-
plicated these genes as AD risk factors [55, 56]. For in-
stance, many of the dysregulated genes identified in this
network, such as TREM2, LPL, ABCA7, and CX3CL1
(Fig. 4), have been linked to AD pathogenesis [57–64].
To further determine whether or not other genes
dysregulated in this network are associated with AD, we
cross-referenced these genes with a list of nominated
AD targets contributed by researchers from the National
Institute on Aging’s Accelerating Medicines Partnership
in Alzheimer’s Disease (AMP-AD) consortium [48, 49].
The AMP-AD has used a wide variety of patient popula-
tions and -omics strategies (genomics, transcriptomics,
proteomics, metabolomics, etc.) to identify novel targets
for late-onset AD therapeutic development. Our cross-
reference analysis revealed that over 90% of the dysregu-
lated genes from the immune-lipid network identified in
the Tg-FDD have been indicated to have a genetic asso-
ciation with LOAD (bolded genes in Fig. 4c and Sup.
Information 1). Overall, the RNA-Seq analysis from Tg-
FDD mice indicates that vascular amyloid pathology
Fig. 2 Glial morphometric changes in Tg-FDD mice. a Individual astrocytes (GFAP, green) were selected, isolated, thresholded, and skeletonized
for analysis from brain sections of WT or Tg-FDD mice. b Quantification of individual astrocyte number of branches and junctions from the
hippocampus and cortex. c Individual microglia (GFAP, green) were selected, isolated, thresholded, and skeletonized for analysis within cortex and
hippocampus in brain sections of WT or Tg-FDD mice d Quantification of individual microglia number of branches and junctions from the
hippocampus and cortex. a and c are representative images of the hippocampus of 9-month-old mice. Results are shown as the mean ± SEM of
n = 4 per genotype and 10–30 astrocytes or microglia per animal, where *p < 0.05 and ****p < 0.0001 as determined by unpaired Student’s t
test. Scale bar 100 μm
Taylor et al. Journal of Neuroinflammation          (2020) 17:223 Page 7 of 18
induces significant transcriptional dysregulation of im-
mune response and lipid processing genes with strong
genetic associations to LOAD, suggesting that some
known AD genetic risk factors could play a preponder-
ant role in CAA pathogenesis.
Considering the perturbations of lipid processing
genes in Tg-FDD mice suggested by the RNA-Seq ana-
lysis, we investigated cholesterol homeostasis in response
to CAA. Cholesterol is highly enriched in the brain [65],
and its accumulation with parenchymal amyloid plaques
Fig. 3 A1 Astrocytes are highly abundant in Tg-FDD. a Double-stained immunofluorescent images of complement component 3 (C3, red) and
astrocytes (GFAP, green) in the hippocampus of WT and Tg-FDD mice. C3 and GFAP immunoreactivity overlay (Merge). b Quantification of
C3+GFAP+ cell % from 3 regions per animal of the hippocampus of 4 WT and 3 Tg-FDD mice. c Quantification of % colocalization area from the
hippocampus of 4 WT and 3 Tg-FDD mice. d Double-stained immunofluorescent images of complement component 3 (C3, red) and astrocytes
(GFAP, green) in the cerebellum of WT and Tg-FDD mice. C3 and GFAP immunoreactivity overlay (Merge). e Quantification of C3+GFAP+ cells %
from 3 regions per animal of the cerebellum of 4 WT and 3 Tg-FDD mice. f Quantification of % colocalization area from the cerebellum of 4 WT
and 3 Tg-FDD mice. a and d are representative images of the brain regions of 9-month-old mice. Colocalization analysis (CC) was performed to
determine pixel intensity correlation between C3 and GFAP signals. White pixels indicate colocalization between C3 and GFAP signal. Plot profiles
of representative C3 and GFAP intensities show higher overlapping of C3 with GFAP in Tg-FDD mice in comparison with WT mice, indicating an
increase of C3 positive astrocytes. Results are shown as the mean ± SEM of n = 3–4. Asterisks indicate significant differences, where **** p <
0.0001 by unpaired Student’s t test. Scale bar 100 μm
Fig. 4 Dysregulation of immune response and lipid processing network in Tg-FDD mice. a Heatmap of gene expression (red = upregulation, blue
= downregulation) and b network analysis of significantly affected genes determined by RNA-Seq in WT versus Tg-FDD mice (n = 3; 9-month-
old). c Bolded genes from lipid processing and immune response network indicate genetic association with LOAD or if the gene has been
nominated as a potential target for AD. logFC, log2 (fold change); FDR, false discovery rate
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has previously been reported in AD patients and in the
brains of transgenic APP mice [66]; however, it has yet
to be investigated in the context of vascular amyloid ac-
cumulation. To investigate cholesterol association with
CAA, we performed filipin staining, a polyene macrolide
antibiotic that binds to cholesterol [67]. Interestingly, we
observed deposits of cholesterol accumulation in 9-
month-old Tg-FDD but not in WT age match controls
nor in 3-month-old Tg-FDD mice (Sup. Fig. 5). These
cholesterol deposits were observed in regions of vascular
amyloid accumulation in this model (Sup. Fig. 1): the
cortex, hippocampus, and cerebellum (Sup. Fig. 5). To
determine if this accumulation of cholesterol was within
the vasculature, we performed double staining for filipin
and α-SMA. No direct colocalization was observed be-
tween filipin staining and smooth muscle cells (Fig. 5a),
suggesting that cholesterol does not accumulate in these
cells, but in other structures or areas of the vasculature.
We then analyzed a possible spatial relationship between
cholesterol accumulation and vascular amyloid. Double
staining revealed a strong colocalization of cholesterol
with vascular amyloid deposits (Fig. 5b). To determine if
cholesterol also accumulates in astrocytes in the Tg-
FDD model, double staining with GFAP and filipin was
performed. Our results show colocalization between
GFAP and filipin only in vascular astrocytes (Fig. 5c),
suggesting that this may result from an association be-
tween reactive astrocytes, vascular amyloid, and choles-
terol deposits, rather than cholesterol accumulation
within the astrocytes. Three-dimensional confocal views
confirmed that cholesterol accumulation is indeed sur-
rounded by activated astrocytes rather than internalized
by astrocytes (Sup. Fig. 6). The colocalization between
cholesterol and vascular amyloid was observed not only
in the cortex (Fig. 5) but also in the hippocampus and
cerebellum. These results demonstrate that cholesterol
Fig. 5 Cholesterol accumulation is associated to vascular amyloid in Tg-FDD mice. a Double immunofluorescence of smooth muscle actin (SMA,
red) and cholesterol fFilipin, green) in Tg-FDD mice show filipin+ staining without association to SMA (Merge). Colocalization analysis (CC) was
performed to determine pixel intensity correlation between filipin and SMA. White pixels indicate colocalization between filipin and SMA signal.
Plot profiles of representative intensities showing almost no overlapping intensities of cholesterol (filipin, green) and SMA (red). b Double
immunofluorescence of Danish amyloid (ADan, red) and cholesterol (filipin, green) in Tg-FDD mice show strong filipin+ colocalization and
overlapping intensities (Merge). Colocalization analysis confirmed major association between filipin and vascular amyloid. White pixels indicate
colocalization between filipin and ADan (red) signal. Plot profiles of representative intensities showing major overlapping intensities of cholesterol
(filipin, green) and ADan (red). c Double immunofluorescence of astrocytes (GFAP, red) and cholesterol (filipin, green) in Tg-FDD mice show
filipin+ show a high degree of cellular association (Merge). White pixels in CC indicate colocalization between filipin and GFAP (red) signal. Plot
profiles of representative intensities showing minor overlapping intensities of cholesterol (filipin, green) and GFAP (red). Scale bar 25 μm
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accumulation is highly associated with vascular amyloid
deposits in CAA, as previously reported for parenchymal
amyloid in AD [66].
As apolipoprotein-E (ApoE) is implicated in regulating
vascular integrity, cholesterol transport, and immune re-
sponses, and ApoE4 allele is the strongest genetic risk
factor for both AD and CAA [68–72], we evaluated
ApoE in Tg-FDD mice. The RNA-Seq analysis did not
reveal changes in ApoE mRNA levels between WT and
Tg-FDD mice. However, ApoE protein levels were sig-
nificantly decreased in the Tg-FDD in comparison with
WT mice (Fig. 6a, b). It has been previously reported
that ApoE accumulates in the brain vasculature in the
Tg-FDD model [37]. Our results confirm this and show
that ApoE colocalizes with vascular amyloid deposits
(Fig. 6c), suggesting that the decrease in ApoE protein
levels (Fig. 6a, b) may be due to a decrease in its solubil-
ity resulting from its association with insoluble vascular
amyloid deposits.
Through the RNA-Seq analysis, we identified TREM2
as one of the upregulated immune-related genes in the
Tg-FDD mouse (Fig. 4). Since TREM2 plays a critical
role in immune regulation and AD pathogenesis [73], we
further characterized this microglial receptor in the con-
text of CAA. We first confirmed the increases in TREM2
mRNA levels in the Tg-FDD model by qPCR (Sup.
Fig. 7). Next, we performed WB to detect the expression
of TREM2 protein. Interestingly, protein levels of
Fig. 6 ApoE is associated with vascular amyloid in Tg-FDD mice. a, b WB analysis and quantification of ApoE from the cerebral hemisphere and
cerebellum of WT and Tg-FDD mice. Vinculin was used as a loading control. For quantifications, error bars represented ± SEM n = 3, where *p <
0.05 of ***p < 0.001, unpaired Student’s t test. c Double immunofluorescence images of apolipoprotein E (ApoE, green) and Danish amyloid
(ADan, red) in WT and Tg-FDD brain sections show a high degree of association of ApoE with vascular amyloid in the Tg-FDD (merge). All are
representative images of 9-month-old mice cortex. Scale bar 100 μm
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TREM2 were significantly decreased in 9-month-old Tg-
FDD mice compared with WT mice (Fig. 7a, c). Add-
itionally, we performed double staining for IBA1 and
TREM2 in WT and Tg-FDD mice. Strikingly, we ob-
served a significant decrease of TREM2-positive micro-
glia in the Tg-FDD model in comparison with WT mice
(Fig. 7b, d). As impairing microglial TREM2 signaling re-
duces neuroinflammatory responses [34, 73, 74], we ana-
lyzed the expression of 30 inflammatory markers from
the RNA-Seq data. No changes in the expression of in-
terleukins were observed; however, expression of chemo-
kines and TNF ligands such as Ccl27a, Cx3cl1, and
C1qtnf4 was decreased in the Tg-FDD model in com-
parison with WT controls (Sup. Fig. 8). This may result
from performing RNA-Seq on whole tissue, which may
mask the unique inflammatory response of specific cell
types. Since A1 astrocytes promote synaptic impairment
[19, 75], we examined the expression of synaptic genes
from the RNA-Seq data. IPA core analysis did not
identify perturbed synaptic gene networks, suggesting no
major synaptic impairment. Nevertheless, when we indi-
vidually analyzed the expression levels of known pre-
and postsynaptic markers, we observed a minor decrease
in the expression of some postsynaptic markers such as
PSD-95 and GABA B2 (Sup. Fig. 9). Overall, these data
suggest that a decrease in TREM2 protein levels is asso-
ciated with early-stage vascular amyloid pathology and
early synaptic impairment in this CAA model.
Since our data suggest that astrogliosis occurs without
significant microgliosis at the early stages of CAA path-
ology, we hypothesize that reactive A1 astrocytes could
affect TREM2 protein levels in microglia. To investigate
the ability of A1 astrocytes to modulate TREM2 protein
levels in microglia, primary astrocyte cultures were
treated with an A1-inducing cocktail of IL-1α, TNFα,
and C1q or PBS (Fig. 8a). Then, primary cultures of
microglia were treated with conditioned media from A1
astrocytes (A1-ACM) or untreated astrocytes control
Fig. 7 Decreased TREM2 protein levels in Tg-FDD mice microglia. aWB analysis and quantification of TREM2 protein levels in the cerebral hemisphere of WT
and Tg-FDD mice. b Double immunofluorescence images of microglia (IBA1, red) and TREM2 (green) in the hippocampus of WT and Tg-FDD mice. cWB
analysis and quantification of TREM2 protein levels in the cerebellum of WT and Tg-FDD mice. d Double immunofluorescence images of microglia (IBA1, red)
and TREM2 (green) in the cerebellum of WT and Tg-FDD mice. For WB analysis (a and c), TREM2 levels were normalized by vinculin. For WB quantifications,
error bars represented ± SEM n = 4, where *p < 0.05 of ***p < 0.001, unpaired Student’s t test. For double immunofluorescence (b and d), a decrease of TREM2
(green) positive microglia (IBA1, red) was observed in WT versus Tg-FDD mice in both brain regions (Merge). Colocalization analysis (CC) was performed to
determine pixel intensity correlation between TREM2 and IBA1. White pixels indicate colocalization between TREM2 and IBA1 signal. All are representative
images of 9-month-old WT or Tg-FDD mice. Scale bar 100μm
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(ACM). Immunofluorescence analysis demonstrated
that, in primary microglia incubated with A1-ACM,
TREM2 protein levels were decreased in comparison
with microglia treated with control ACM (Fig. 8b, c).
Interestingly, no significant microglial activation was ob-
served in cultures treated with A1-ACM (Fig. 8d). These
results indicate that A1 astrocytes may affect TREM2
protein levels without inducing major microglial
activation.
Discussion
This study demonstrates that early pathology in a mouse
model of CAA is associated with severe astrogliosis with an
A1 astrocytic phenotype without significant microgliosis.
Additionally, the immune response and lipid processing net-
work are dysregulated in the Tg-FDD model. Further, valid-
ation demonstrated an impairment of cholesterol, ApoE, and
TREM2 in this CAA model, as has been broadly demon-
strated in AD mouse models, characterized by the
accumulation of parenchymal amyloid plaques. Finally, A1
astrocytes induce a decrease in TREM2 protein levels in
microglial culture.
The role of glial cells in the pathogenesis of several neu-
rodegenerative diseases, including AD, has been a major
research focus in recent years [10–16]. Since astrocytes
and microglia activation has been described in CAA pa-
tients [29, 76], we studied the early glial response associ-
ated with early CAA pathology in Tg-FDD mice. Here, we
report that vascular amyloid deposition in 9-month-old
Tg-FDD animals contributes to robust immunoreactive
and morphometric changes in astrocytes with increased
glial branches and junctions in early CAA. Interestingly,
astrocytic alterations associated with a premature vascular
amyloid accumulation have also been reported in trans-
genic artic β-amyloid (acrAβ) mice [77], suggesting that
severe astrocytic reactivity in early CAA is independent of
amyloid species. In response to early vascular amyloid ac-
cumulation, microglial reactivity is unchanged, with no
Fig. 8 A1 astrocyte conditioned media decreases TREM2 protein in mouse primary microglia culture. a Schematic diagram showing A1 astrocytes
induction by cytokine cocktail treatment (TNFα, IL-1α, and C1q) followed by microglia incubation with astrocyte conditioned media (ACM) from
A1 astrocytes or control astrocytes solely treated with PBS. b Double immunofluorescence images of microglia (IBA1, red) and TREM2 (green) of
primary WT mouse microglia culture treated with control or A1 ACM. Right panel shows orthogonal images of reconstructed three-dimensional
views. c Intensity quantification of TREM2 per cell shows a decrease in TREM2 proteins in microglia incubated with A1 ACM. d Quantification of
IBA1+ cell surface area shows no change in cell surface area between control and A1 ACM-treated groups. For quantifications, error bars
represented ± SEM where eight to ten images were used for each experiment with n = 3 independent cultures and 20 cells per culture, where
****p < 0.0001 by unpaired Student’s t test. Scale bar 50 μm
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CD11B or IBA1 immunoreactive or morphometric
changes in glial branches or junctions. Traditionally, stud-
ies of AD mouse models with parenchymal amyloid accu-
mulation report the presence of both activated astrocytes
and microglia [78–81]; however, our findings demon-
strated that in a mouse model of CAA robust astrogliosis
independent of microglial immune activation is a primary
response to vascular amyloid deposition. The early astro-
cytic response in CAA could be due to the central role of
astrocytes in the neurovascular unit in maintaining BBB
integrity and cerebral blood flow regulation in physio-
logical and pathological conditions [82–84]. For instance,
changes in vascular components due to CNS injury have a
direct influence on astrocyte signaling [85]. Astrocytes re-
spond to and influence immune and inflammatory re-
sponses following insults such as excitotoxicity, ischemia,
apoptosis, necrosis, and inflammatory cues by undergoing
a pronounced transformative state called “reactive astro-
gliosis”, regulating inflammatory responses that can be ei-
ther neuroprotective or neurotoxic and participating in
migratory, phagocytic, and proteolytic activity [72]. The
notion that the astrocyte and microglia phenotype ob-
served in 9-month-old Tg-FDD results from a response to
vascular amyloid deposits as opposed to overexpression of
the mutant form of human BRI2 is supported by the fact
that the transgene expression is under the control of the
mouse prion promoter, which is exclusively expressed in
neurons [37]. Therefore, no BRI2 is over-expressed in glial
cells. The role of CAA in glial response in this model is
also supported by the observation that no astrogliosis is
detected in 3-month-old Tg-FDD mice, an age where no
vascular amyloid deposits are observed [37].
It has recently been shown that activated microglia
may directly polarize A1 astrocytes toward a neuro-
toxic phenotype [19]. Induced by a cytokine cocktail
composed by TNFα, IL-1α, and C1q, A1 astrocytes
can be identified by their upregulation of C3 and are
shown to lose many normal homeostatic functions,
such as the promotion of neuronal survival, neurite
outgrowth, and synapse formation. This suggests that
A1s are either unable to maintain synapses or actively
disassemble them by releasing multiple complement
components that help drive synaptic degeneration. A1
astrocytes also exert a toxic gain of function by se-
creting soluble neurotoxin(s) that induce neuronal
and oligodendrocyte death, supporting the notion that
A1 astrocytes are involved in the development of neu-
rodegenerative diseases [19, 86]. In this study, we re-
port for the first time that A1 astrocytes are highly
abundant in a mouse model of CAA. No activated
microglia were observed at early stages of CAA path-
ology, suggesting that inflammatory signaling derived
from another source may be responsible for, and suf-
ficient, to induce A1 astrocytes in CAA. While it is
unknown if damaged endothelial or vascular cells
polarize astrocytes to an A1 type, each can produce
pro-inflammatory cytokines under toxic stimulation,
supporting the notion that these cells are capable of
A1 astrocytic induction [87, 88]. Blocking A1 astro-
cyte conversion is neuroprotective in Parkinson’s dis-
ease models [21]; however, their abolishment
accelerated prion disease course in a mouse model
[22]. This suggests that the role of these astrocytes is
disease-specific, and further analysis is required to de-
termine their contribution to CAA pathogenesis.
Recently, genome-wide association studies (GWAS),
whole-genome sequencing (WGS), and gene-expression
network analyses have revealed gene networks and com-
mon and rare genetic variants that are associated with
LOAD. The majority of these genes are involved in lipid
processing, endocytosis, and innate immunity [55, 56,
89, 90]. Further validations of many of these risk factors
have focused on their effect on parenchymal amyloid
pathology, with their influence in vascular amyloid path-
ology largely understudied. Gene expression analyses re-
vealed dysregulation of immune response networks
associated with lipid processing in the Tg-FDD model.
Our RNA-Seq results showed an upregulation of the
rare AD-associated genetic factors ABCA7 and TREM2
[57, 58], an upregulation of lipoprotein lipase (LPL),
known to be involved in AD susceptibility and patho-
genesis [59, 60], and downregulation of CX3CL1, which
has known roles in neuroprotection and neurotoxicity in
the context of AD [61–64]. This suggests that many of
the immune and lipid-related genes, identified as risk
factors for AD, may have a preponderant involvement in
CAA pathogenesis. In support of this, a recent
population-based study tested the association of distinct
neuropathological features of AD with risk loci identified
in GWAS studies. Remarkably, the authors observed an
association between the ABCA7 and TREM2 loci with
CAA and capillary-Aβ, respectively [91], further demon-
strating a role for immune-related AD risk factors in
vascular amyloid deposition.
Multiple threads of evidence connect cholesterol with
AD [92]. Epidemiological studies suggest a positive cor-
relation between hypercholesterolemia and increased
AD risk, though the exact impact and mechanisms in-
volved remain largely unknown. Previous reports have
shown cholesterol accumulation in senile plaques of AD
patients and mouse models alike [66], suggesting that
cholesterol could play a role in the formation of amyloid
plaques, and that amyloid impairs cholesterol trafficking
and homeostasis. Here, our findings show prominent
cholesterol accumulation associated with vascular amyl-
oid in the Tg-FDD. This indicates that the dysregulation
of cholesterol redistribution in CAA could play an im-
portant role in disease progression.
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ApoE, predominantly produced by astrocytes, has been
widely confirmed to regulate the redistribution and
homeostasis of cholesterol within the brain and to affect
the accumulation and clearance of Aβ-amyloid [70, 93,
94]. Here, we observed an association between ApoE
and vascular amyloid deposits in Tg-FDD mice, possibly
decreasing its solubility. These observations are sup-
ported by previous studies implicating ApoE as the prin-
cipal component of parenchymal amyloid plaques and
CAA [95, 96] and the major risk factor for both AD [97]
and CAA [98]. The ApoE4 isoform is associated with
total and vascular Aβ-amyloid levels [99], and the ApoE2
isoform is a risk factor for hemorrhagic CAA [97, 98].
Conversely, the ApoE2 isoform is protective in AD [100],
suggesting that the mechanistic basis of ApoE-amyloid
association differs between AD and CAA. The different
influence of ApoE on the development of parenchymal
plaques versus CAA has also been observed in mouse
models. For instance, the over-expression of human
ApoE4 in the APP
swe mouse model, characterized by the
accumulation of amyloid plaques, results in a shift in the
amyloid deposition from parenchyma to the vasculature
[101]. Also, it was recently shown how in the 5XFAD
model expressing murine ApoE and human ApoE4 par-
enchymal plaques colocalized with much more murine
ApoE while vascular amyloid deposits contained more
human ApoE4, suggesting that the type of ApoE dictates
whether ApoE will lead to greater parenchymal plaques
versus CAA [102]. Additional studies will be required to
determine if ApoE impairment in the context of vascular
amyloid originates from astrocytes or microglia. Peri-
cytes may also be involved as a recent study demon-
strated that ApoE plays a critical role in these vascular
cells in the context of CAA [103].
The role of TREM2 in AD has become increasingly
relevant as human variants of TREM2 have been associ-
ated with a 2- to -3-fold increased risk for developing
LOAD [104]. Several cellular functions have been as-
cribed to TREM2, including the regulation of phagocyt-
osis, inhibition of inflammatory signaling, promotion of
cell survival, and cholesterol efflux [105, 106]. New stud-
ies have demonstrated that several apolipoproteins, in-
cluding ApoE, are TREM2 ligands, and that the APOE-
TREM2 pathway plays a fundamental role in the micro-
glial homeostatic signature [15, 107]. However, the ma-
jority of TREM2 studies in AD relate to parenchymal
amyloid deposition, and the role of TREM2 in vascular
amyloid deposition and CAA is largely unknown [31, 34,
72, 73, 105]. Here, we demonstrated an increase in
TREM2 mRNA levels in the Tg-FDD model in compari-
son with WT controls. Recently, a novel study demon-
strated an increase in TREM2 mRNA levels in a rat
model for CAA [108], supporting our findings. Interest-
ingly, our biochemical analysis revealed a significant
decrease in TREM2 protein levels. It is well known that
transcriptome changes do not always correlate with pro-
tein abundance [109]; nevertheless, this discrepancy be-
tween mRNA and protein levels suggests the presence of
either a post-translational mechanism promoting
TREM2 degradation, or a post-translational modification
directly in the TREM2 protein that decreases its stability.
This decrease in protein levels could trigger an increase
in TREM2 mRNA expression as a compensatory mech-
anism. Noteworthily, despite the significant decrease in
TREM2 protein levels, no changes in microglial immu-
noreactivity were observed, suggesting that the decrease
of TREM2 could be an early response of microglial
reactivity to vascular amyloid deposits. Similar observa-
tions were made in an APP/PS1 mouse model character-
ized by the accumulation of parenchymal amyloid
plaques, where the authors reported an increase of
TREM2 mRNA and a decrease of TREM2 protein [110].
It was suggested that the lack of TREM2 protein may re-
duce microglia activity, ultimately leading to neuroin-
flammation [110]. Collectively, these data indicate that
TREM2-related pathways could have an influence on
vascular amyloidosis. Further, studies will be necessary
to dissect in detail the effect of TREM2 in CAA [104]
and the effect that ApoE impairment has on TREM2 via
its ligand function [107] or the recently identified
TREM2-APOE regulatory pathway responsible for
microglial phenotypic change [15].
The decrease in TREM2 protein levels without signifi-
cant changes in microglial reactivity in early vascular
amyloid deposits in the Tg-FDD model is an unexpected
and unique finding. However, activation of microglia can
result in phenotypic and functional diversity—detrimen-
tal or beneficial—depending on the activation condi-
tions. This duality in microglia has been reported in
detail, but complex mechanisms that regulate these di-
verse states of activation remain unclear [111, 112]. It
has been suggested that different stages of microglial ac-
tivation may also depend on signaling from another
CNS cell type [113]. Therefore, based on our analysis of
the Tg-FDD model, where a preponderant A1 astrocyte
reactivity was observed at the early stages of vascular
amyloid pathology, we theorized that A1 astrocytes may
contribute to microglia activation and decreased TREM2
levels. Interestingly, we observed that treating primary
microglia with conditioned A1-ACM media decreases
TREM2 intensity without significantly affecting micro-
glia morphology, demonstrating the ability of A1 astro-
cytes to influence microglial steady state. The concept of
A1 astrocytes influencing microglial activation is particu-
larly interesting as studies have mainly focused on the
ability of reactive microglia to influence A1 astrocytic
phenotypes in disease and injury [19]; however, this con-
cept has not been thoroughly explored in the context of
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astrocytes influencing microglia reactivity. Only a hand-
ful of studies have suggested a direct effect of astrocytes
on microglia [114]. For instance, a high level of S100ß
production in astrocytes contributes to iNOS and NO
production in microglia [115]. In another study, astro-
cytes were able to downregulate the antigen-presenting
function of invading monocytes [116]. Furthermore, a
new study demonstrated that exposure to conditioned
media from oxygen-glucose-deprived astrocytes acti-
vated microglia-promoted neuronal dendritogenesis
[113]. Overall, these studies support the notion that in
the Tg-FDD model, A1 astrocytes could secrete factor(s)
that affect TREM2 protein stability and subsequently
microglial activity.
Identifying the signals or factors used by A1 astrocytes
to alter TREM2 protein levels in microglia and the role
that ApoE could play provides a means to potentially
regulate the neuroinflammatory response associated with
CAA pathogenesis and in other cerebrovascular diseases
where astrocytic reactivity could precede microglial
response.
Conclusions
Our study demonstrates that initial glial response associ-
ated with early-stage CAA is characterized by the upreg-
ulation of A1 astrocytes without significant microglial
reactivity. This glial response is distinct from AD, where
reactive microglia influence the A1 astrocyte phenotype.
Noteworthy, gene expression analysis revealed that sev-
eral AD risk factors involved in immune response and
lipid processing could also have a preponderant role in
CAA. This study contributes to the increasing evidence
that brain cholesterol metabolism, ApoE, and TREM2
signaling are major players in the pathogenesis of AD-
related dementias, including CAA. Understanding the
basis for possible differential effects of the glial response,
ApoE, and TREM2 signaling on parenchymal plaques
versus vascular amyloid deposits provides important
insight into neuroimmune mechanisms further under-
standing of neurodegenerative processes associated with
AD and CAA, respectively, and promote the develop-
ment of novel therapeutics and prevention strategies.
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Additional file 1: Supplementary-Figure 1. Early vascular amyloid
deposition in a transgenic mouse model for Familial Danish Dementia
(Tg-FDD). Thio-S staining of brain from 9-month-old Tg-FDD mice dem-
onstrated the presence of vascular amyloid deposits in the cortex, hippo-
campus, and cerebellum. Scale bar 50 μm or 100 μm.
Additional file 2: Supplementary-Figure 2. No changes in microglia
immunoreactivity is observed in Tg-FDD. Double immunofluorescence
images of amyloid (Thio-S, green) and CD11B (red) in the cortex,
hippocampus, and cerebellum of 9-month-old WT or Tg-FDD mice
showed no differences in CD11B % area. Results are shown as the mean
± SEM of n = 3-4. No significant differences where observed by Unpaired
Student's t test. Scale bar 100 μm.
Additional file 3: Supplementary-Figure 3. Reactive astrogliosis is
accentuate in the perivascular regions in Tg-FDD mice. Triple immuno-
fluorescence of astrocytes (GFAP, cyan), amyloid (Thio-S, green), and
smooth muscle actin (SMA, red) in the cortex, hippocampus, and cerebel-
lum of 9-month-old Tg-FDD mice and WT controls. Major presence of re-
active astrogliosis is observed in the perivascular region of Thio-S positive
vasculature in Tg-FDD mice. Scale bar 50 μm.
Additional file 4: Supplementary-Figure 4. No glial immunoreactive
is observed in 3-month-old Tg-FDD mice. A) Double immunofluorescence
images of amyloid (Thio-S, green) and astrocytes (GFAP, red) and quantifi-
cation of GFAP+ area (%) in WT and Tg-FDD mice. B) Double immuno-
fluorescence images of amyloid (Thio-S, green) and microglia (IBA1, red)
and quantification of IBA1+ area (%) in WT and Tg-FDD mice. All are rep-
resentative images of the brain regions of 3-month-old WT or Tg-FDD
mice. Results are shown as the mean ± SEM of n = 3. No significant dif-
ferences where observed by Unpaired Student's t test. Scale bar 100 μm.
Additional file 5: Supplementary-Figure 5. Cholesterol accumulation
in Tg-FDD. The presence of cholesterol was detected by fluorescent mi-
croscopy images using Filipin (green). Cholesterol accumulation is not
observed prior to CAA pathology in 3-month-old Tg-FDD or in 9-month-
old WT animals but is observed at early stages of CAA deposition in 9-
month-old Tg-FDD mice. Scale bar 100 μm.
Additional file 6: Supplementary-Figure 6. Reactive astrocytes cluster
around cholesterol deposits in Tg-FDD mice. Double immunofluores-
cence of astrocytes (GFAP, red) and cholesterol (Filipin, green) in Tg-FDD.
Three-dimensional view shows that astrocytes are surrounding choles-
terol deposits. Scale bar 50 μm.
Additional file 7: Supplementary-Figure 7. Increased TREM2 mRNA
levels in cerebral hemisphere and cerebellum in Tg-FDD mice. mRNA
levels of TREM2 in the cerebral hemisphere and cerebellum of 9-month-
old WT and Tg-FDD mice were measured by quantitative reverse
transcription-PCR (qRT-PCR). Data was normalized to the levels of GAPDH
mRNA. Relative quantitation was performed using 2-ΔΔCt (fold change)
method. Results are shown as the mean ± SEM of n = 3. Asterisks indi-
cate significant differences, where * p < 0.05 and ** p < 0.01.
Additional file 8: Supplementary-Figure 8. No major changes are
observed in inflammatory and chemotactic markers in Tg-FDD mice. A)
RNA-Seq data from 9-month-old Tg-FDD and WT mice showed no differ-
ence in expression of interleukins such as IL-1a, IL 15, IL33, IL 22, IL 16, IL
34, IL12a, IL 18, and IL 11. B) The only tumor necrosis factor ligand that
statistically decreased in Tg-FDD was C1qtnf4. C) No major changes in
chemokines expression were observed in Tg-FDD mice. Only Ccl27a and
CX3CL1 were statistically decreased. Results are shown as the mean ±
SEM of n = 3. Asterisks indicate significant differences, where **** p <
0.0001. RPKM = Reads Per Kilobase of transcript, per Million mapped
reads.
Additional file 9: Supplementary-Figure 9. Synaptic markers
expression in Tg-FDD mice. RNA-Seq data from 9-month-old Tg-FDD and
WT mice showed no difference in presynaptic markers synaptophysin
(Syp), Synapsin 1 (Syn1), Synapsin 2 (Syn2), and Synapsin 3 (Syn3). No
changes were observed in the postsynaptic markers GLUR1 and GluN1.
The postsynaptic markers PSD95 and GABA B2 were statistically decreased
in Tg-FDD in comparison with WT mice. Results are shown as the mean
± SEM of n = 3. Asterisks indicate significant differences, where * p < 0.05
and ** p < 0.01. RPKM = Reads Per Kilobase of transcript, per Million
mapped reads.
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